MECOM and acute myeloid leukemia: We describe a case of ETV6‐MECOM fusion‐positive refractory AML, where molecular analysis and in vitro high throughput drug screening identified a tolerable, novel targeted therapy and provided rationale for avoiding what could have been a toxic treatment regimen.